Nicolas Hulscher, MPH
@NicHulscher
·
1h
BREAKING STUDY: Nattokinase Breaks Down SPIKE PROTEIN, AMYLOID MICROCLOTS, BLOOD CLOTS, and SHRINKS ARTERIAL PLAQUE
We assembled DECADES of evidence to uncover the powerful MULTI-TARGET EFFECTS of nattokinase:
- Degrades spike protein
- Breaks down harmful amyloid proteins
- Dissolves abnormal amyloid microclots
- Breaks down fibrin blood clots
- Boosts the body’s natural clot-dissolving system
- Shrinks arterial plaque
- Lowers blood pressure
- Reduces blood-clotting factors and platelet clumping
Our new paper, “Proteolytic Targets and Clinical Benefits of Oral Nattokinase: Spike Protein and Amyloid Degradation, Fibrinolysis, and Cardiovascular Risk Reduction,” was produced through a collaboration between The Wellness Company and the McCullough Foundation.
It represents one of the most comprehensive evaluations of nattokinase to date, uniquely integrating its proteolytic, cardiovascular, pharmacokinetic, amyloid, and spike-protein literature into a single paper.
After oral dosing, nattokinase-related activity shows up in human blood and changes clotting and clot-breakdown markers within hours.
Three independent labs have now shown that nattokinase-related enzymes can BREAK DOWN SPIKE PROTEIN in vitro—including purified nattokinase itself.
At higher doses, human imaging studies reported about a 36% SHRINKAGE in carotid artery plaque—suggesting the effective range may begin around 6,000 FU/day.
Randomized human trials also show modest BLOOD-PRESSURE reductions with nattokinase, with pooled decreases of about 3.5 mmHg systolic and 2.3 mmHg diastolic.
And in long-term population studies, higher natto intake was associated with a 25% LOWER RISK of cardiovascular death and a 32% LOWER RISK of stroke death.
Nattokinase has been well tolerated across human studies, with no notable adverse events reported across six randomized trials. Even 10,800 FU/day for 12 months was used in a large observational cohort without reported excess bleeding.
This inexpensive, orally available enzyme holds immense promise for cardiovascular risk reduction in the post-COVID era.
It now deserves large-scale clinical testing for cardiovascular risk reduction and other post-vaccination injury applications.
We plan to launch some of these studies shortly.
@twc_health
@McCulloughFund
@P_McCulloughMD
@DrHarveyRisch
@DrKellyVictory
@jathorpmfm
@drdrew
@PeterGillooly
September 22, 2026
GROK Summary:
- The X post by epidemiologist Nicolas Hulscher announces a new review paper on Zenodo synthesizing evidence for nattokinase, a serine protease from fermented soybeans, claiming it degrades spike protein and amyloids in vitro, dissolves fibrin clots, reduces arterial plaque, and lowers blood pressure.
- Peer-reviewed lab studies, including a 2022 Molecules paper, confirm nattokinase breaks down SARS-CoV-2 spike protein in a dose- and time-dependent manner in cell cultures, while human trials show modest systolic/diastolic BP reductions of ~3.5/2.3 mmHg and up to 36% carotid plaque shrinkage at higher doses like 6,000+ FU/day.
- The review, co-authored by McCullough Foundation affiliates, highlights nattokinase's fibrinolytic activity and safety profile across studies but notes the spike protein and microclot benefits remain primarily preclinical, calling for larger clinical trials in post-COVID contexts.
